Abstract
We present clinical practice recommendations for the treatment of children with Alport syndrome who are not enrolled in clinical trials. Our goal is to promote early initiation of a standard therapeutic approach that will facilitate assessment of the safety and efficacy of the protocol. The treatment protocol is based on the reduction of proteinuria, intraglomerular pressure, and renal fibrosis via interference with the renin-angiotensin-aldosterone system.
Original language | English (US) |
---|---|
Pages (from-to) | 5-11 |
Number of pages | 7 |
Journal | Pediatric Nephrology |
Volume | 28 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2013 |
Bibliographical note
Funding Information:The Alport Syndrome Treatments and Outcomes Registry (C.K., M.G., M.R., C.L.) receives support from private donors and the Alport Syndrome Foundation ( www.alportsyndrome.org ). The European Alport Registry is supported by the Association pour l’Information et la Recherche sur les Maladies Rénales Génétiques (AIRG) (to O.G.) and the KfH Foundation Preventive Medicine (Fritz-Scheler Stipendium of the German Society of Nephrology) (to O.G.). The EARLY PRO-TECT Alport trial is funded by the German Ministry of Education and Research (O.G.).
Keywords
- Aldosterone inhibitor
- Alport syndrome
- Angiotensin receptor blocker
- Angiotensin-converting enzyme inhibitor
- Proteinuria